Inspira Technologies Moves Into Liquid Biopsy With Planned Acquisition and $15 Million Strategic Investment

Inspira Technologies Oxy BHN ( (IINN) ) has issued an announcement.

On January 5, 2026, Inspira Technologies Oxy B.H.N. Ltd. signed a non-binding term sheet to acquire an advanced liquid biopsy cancer diagnostics business in an all-share deal, exchanging 40% of its fully diluted share capital and securing a concurrent $15 million strategic equity investment at a pre-money valuation of $180 million. The move would shift Inspira into the fast-growing liquid biopsy market via a development-ready platform that uses AI to analyze circulating tumor cells, initially focused on breast cancer, with plans to pursue FDA 510(k) clearance and benefit from an existing reimbursement code. To bridge the period until a definitive acquisition agreement, Inspira also issued a binding senior convertible debenture on January 5, 2026, lending the target company $1 million at 10% annual interest, with conversion features tied to Tel Aviv Stock Exchange rules and a 19.99% ownership cap. The company intends to allocate up to $12 million of the new equity proceeds to support its existing respiratory and blood monitoring operations, while a contingent value rights structure is designed to preserve the economic upside from these legacy assets exclusively for current shareholders, underscoring management’s effort to mitigate dilution and reposition Inspira as a dual-platform MedTech player spanning life-support and oncology diagnostics.

The most recent analyst rating on (IINN) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.

The score is weighed down primarily by very weak financial performance (ongoing losses, negative gross profit, and significant cash burn with reliance on external funding). Technicals are also weak with negative momentum and trading below most key moving averages. Valuation provides little support because the negative P/E reflects unprofitable operations and there is no dividend yield.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is used for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., forming the basis for the next-generation INSPIRA ART500, which is designed to provide oxygenation to awake, spontaneously breathing patients. The company is also developing HYLA, a proprietary blood sensor platform for continuous, non-invasive monitoring, and positions itself as a life-support and MedTech platform with a growing intellectual property portfolio and streamlined operations.

Average Trading Volume: 188,756

Technical Sentiment Signal: Strong Sell

Current Market Cap: $32.87M

See more data about IINN stock on TipRanks’ Stock Analysis page.